First‐Line Osimertinib in Patients with EGFR ‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study-Reference-Cited by-同舟云学术

First‐Line Osimertinib in Patients with EGFR ‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

Published:2021-09-19 Issue: Volume: Page:
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:The Oncol

Author:

Lorenzi Martina¹²,Ferro Alessandra¹²,Cecere Fabiana³,Scattolin Daniela¹,Del Conte Alessandro⁴,Follador Alessandro⁵,Pilotto Sara⁶,Polo Valentina⁷,Santarpia Mariacarmela⁸,Chiari Rita⁹,Pavan Alberto⁹,Maso Alessandro Dal¹²,Da Ros Valentina⁴,Targato Giada⁵,Vari Sabrina¹⁰,Indraccolo Stefano¹¹,Calabrese Fiorella¹²,Frega Stefano²,Bonanno Laura²,Conte Pier Franco¹²,Guarneri Valentina¹²,Pasello Giulia¹²^ORCID

Affiliation:

1. Department of Surgery, Oncology, and Gastroenterology, University of Padova Padova

2. Division of Medical Oncology 2, Veneto Institute of Oncology – IRCCS Padova

3. Oncology 1, Regina Elena National Cancer Institute – IRCCS Padova Italy

4. Medical Oncology and Immunorelated Tumors, National Cancer Institute Centro di Riferimento Oncologico (CRO) – IRCCS Aviano (PN) Italy

5. Department of Medical Oncology, Azienda Sanitaria Universitaria Integrata of Udine, Santa Maria della Misericordia Hospital Udine Italy

6. Oncology Department, Azienda Ospedaliera Universitaria Integrata di Verona Verona Italy

7. Oncology Unit, Azienda Unità Locale Socio Sanitaria (AULSS 2) Marca Trevigiana, Ca’ Foncello Hospital Treviso Italy

8. Department of Human Pathology “G. Barresi”, University of Messina Messina Italy

9. Medical Oncology, AULSS 6 Euganea, South Padua Hospital Monselice (PD) Italy

10. Oncology 1, Regina Elena National Cancer Institute – IRCCS Rome Italy

11. Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV – IRCCS Padua Italy

12. Cardiovascular Pathology Unit, Department of Cardio‐Thoracic and Vascular Sciences, University of Padova Padova Italy

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/onco.13951

Reference31 articles.

1. Osimertinib in untreated EGFR ‐mutated advanced non–small‐cell lung cancer;Soria JC;N Engl J Med,2017

2. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

3. Analysis of time‐to‐treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non‐small‐cell lung cancer;Blumenthal GM;Ann Oncol,2019

4. Osimertinib or platinum‐pemetrexed in EGFR T790M‐positive lung cancer;Mok TS;N Engl J Med,2017

5. Afatinib versus cisplatin plus gemcitabine for first‐line treatment of Asian patients with advanced non‐small‐cell lung cancer harbouring EGFR mutations (LUX‐Lung 6): An open‐label, randomised phase 3 trial;Wu YL;Lancet Oncol,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significant Prognostic Factor at Age Cut-off of 73 Years for Advanced Ovarian Serous Cystadenocarcinoma Patients: Insights from Real-World Study;International Journal of Women's Health;2024-02

2. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation;Journal of Thoracic Disease;2023-11

3. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study;Translational Lung Cancer Research;2023-11

4. Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer;International Journal of Cancer;2023-10-15

5. Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study;JTO Clinical and Research Reports;2023-10